Fate Therapeutics (FATE) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Fate Therapeutics (FATE) over the past year, gaining 74.5% versus a gain of 54.7%. Over five years, STRO leads with a -92.3% price change compared with -96.5% for FATE. Fate Therapeutics is the larger company by market cap ($257.6 million vs $243.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | STRO |
|---|---|---|
| Share price | $2.15 | $14.66 |
| Market cap | $257.61M | $243.08M |
| 1-day change | -6.11% | +1.45% |
| YTD return | +119.39% | +26.71% |
| 1-year return | +54.68% | +74.52% |
| 5-year return | -96.49% | -92.28% |
| EPS (TTM) | $-1.05 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.23 | $43.85 |
| 52-week low | $0.95 | $7.15 |
| Distance from 52-week high | -33.44% | -66.57% |
| Average volume | 1.90M | 289.73K |
| Shares outstanding | 119.82M | 16.58M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed FATE by 19.8 percentage points over the past year.
FATE vs STRO FAQ
Which is bigger, Fate Therapeutics or Sutro Biopharma?
Fate Therapeutics (FATE) is larger, with a market capitalization of $257.61M compared with $243.08M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, FATE or STRO?
STRO returned +74.52% over the past 12 months, compared with +54.68% for FATE (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.